CORONA Remedies Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 29.5%)
- Efficient capital deployment (ROCE 33.3%)
- Low debt relative to equity (D/E 0.2x)
Concerns
- High premium to book value (P/B 17.2x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Rs 10 Per Share
To consider and approve the financial results for the period ended March 31, 2026 and recommend final dividend, if any, on the equity shares of the Company for the financial year ended March 31, 2026.
Latest News
All newsCORONA Remedies hosts analyst and investor meet.
*CORONA Remedies hosts analyst and investor meet.* The company conducted an update session for institutional investors and analysts. No major financial announcements or guidance changes were disclosed. Event scheduled per NSE corporate filing. 📊 *STOCKS:* $CORONAREMED | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
CORONA Remedies to hold shareholder meeting on July 09, 2026
*CORONA Remedies to hold shareholder meeting on July 09, 2026.* The company has scheduled a meeting of shareholders for **July 09, 2026**, as per its NSE filing. Purpose of the meeting is not specified in the notice. Such meetings typically address routine corporate matters or resolutions. 📊 *STOCKS:* CORONAREMED | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholderMeeting
Corona Remedies announces 22nd AGM and record date
*Corona Remedies announces 22nd AGM and record date.* The company has published notice of its 22nd Annual General Meeting with intimation of record date and e-voting details. Shareholders as of the record date will be eligible to vote. The announcement is part of routine corporate compliance. 📊 *STOCKS:* CORONAREMED | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AGM
CORONA Remedies to host analyst and investor call.
*CORONA Remedies to host analyst and investor call.* The company has scheduled a conference call for analysts and institutional investors. This event is part of routine investor communication. No financial updates or major announcements were disclosed. 📊 *STOCKS:* CORONAREMEDY | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
Financials
Quarterly Results
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹422 Cr 19.5% | ₹353 Cr 3.2% | ₹342 Cr 5.3% | ₹361 Cr 4.0% | ₹347 Cr 18.0% | ₹294 Cr 1.3% | ₹298 Cr 5.1% | ₹314 Cr |
| Op. Profit | ₹93 Cr 50.0% | ₹62 Cr 25.3% | ₹83 Cr 6.4% | ₹78 Cr 11.4% | ₹70 Cr 29.6% | ₹54 Cr 21.7% | ₹69 Cr 3.0% | ₹67 Cr |
| OPM | 22.0% 22.2% | 18.0% 25.0% | 24.0% 9.1% | 22.0% 10.0% | 20.0% 11.1% | 18.0% 21.7% | 23.0% 9.5% | 21.0% |
| Net Profit | ₹60 Cr 33.3% | ₹45 Cr 9.8% | ₹41 Cr 21.2% | ₹52 Cr 13.0% | ₹46 Cr 43.8% | ₹32 Cr 28.9% | ₹45 Cr 4.7% | ₹43 Cr |
| EPS (₹) | 9.83 32.7% | 7.41 9.8% | 6.75 21.1% | 8.55 13.2% | 7.55 46.3% | 5.16 29.8% | 7.35 4.6% | 7.03 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | ₹1.4K Cr 17.3% | ₹1.2K Cr 17.9% | ₹1.0K Cr 14.7% | ₹884 Cr |
| Expenses | ₹1.1K Cr 16.0% | ₹956 Cr 11.3% | ₹859 Cr 13.6% | ₹756 Cr |
| Op. Profit | ₹294 Cr 22.0% | ₹241 Cr 54.5% | ₹156 Cr 21.9% | ₹128 Cr |
| OPM | 21.0% 5.0% | 20.0% 33.3% | 15.0% 7.1% | 14.0% |
| Other Income | ₹-9 Cr 250.0% | ₹6 Cr 20.0% | ₹5 Cr 28.6% | ₹7 Cr |
| Interest | ₹7 Cr 36.4% | ₹11 Cr 21.4% | ₹14 Cr 250.0% | ₹4 Cr |
| Depreciation | ₹38 Cr 2.7% | ₹37 Cr 32.1% | ₹28 Cr 40.0% | ₹20 Cr |
| PBT | ₹240 Cr 20.6% | ₹199 Cr 68.6% | ₹118 Cr 6.3% | ₹111 Cr |
| Tax % | 23.0% 8.0% | 25.0% 4.2% | 24.0% 4.3% | 23.0% |
| Net Profit | ₹185 Cr 24.2% | ₹149 Cr 65.6% | ₹90 Cr 5.9% | ₹85 Cr |
| EPS (₹) | 30.27 23.9% | 24.43 65.1% | 14.8 6.6% | 13.89 |
| Div Payout | 33.0% 10.0% | 30.0% 20.0% | 25.0% 25.0% | 20.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
Liabilities | |||||
| Equity Capital | ₹61 Cr 0.0% | ₹61 Cr 0.0% | ₹61 Cr 0.0% | ₹61 Cr 0.0% | ₹61 Cr |
| Reserves | ₹686 Cr 14.7% | ₹598 Cr 9.7% | ₹545 Cr 30.1% | ₹419 Cr 20.7% | ₹347 Cr |
| Borrowings | ₹165 Cr 161.9% | ₹63 Cr 26.7% | ₹86 Cr 45.9% | ₹159 Cr 467.9% | ₹28 Cr |
| Other Liabilities | ₹293 Cr 15.4% | ₹254 Cr 7.2% | ₹237 Cr 24.1% | ₹191 Cr 20.1% | ₹159 Cr |
| Total Liabilities | ₹1.2K Cr 23.3% | ₹977 Cr 5.1% | ₹930 Cr 11.9% | ₹831 Cr 39.7% | ₹595 Cr |
Assets | |||||
| Fixed Assets | ₹554 Cr 40.6% | ₹394 Cr 6.5% | ₹370 Cr 3.6% | ₹384 Cr 107.6% | ₹185 Cr |
| CWIP | ₹143 Cr 30.2% | ₹205 Cr 10.2% | ₹186 Cr 53.7% | ₹121 Cr 86.2% | ₹65 Cr |
| Investments | ₹26 Cr | ₹0 Cr 100.0% | ₹26 Cr 0.0% | ₹26 Cr 18.8% | ₹32 Cr |
| Other Assets | ₹482 Cr 27.5% | ₹378 Cr 8.6% | ₹348 Cr 15.6% | ₹301 Cr 4.1% | ₹314 Cr |
| Total Assets | ₹1.2K Cr 23.3% | ₹977 Cr 5.1% | ₹930 Cr 11.9% | ₹831 Cr 39.7% | ₹595 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating CF | ₹229 Cr 20.5% | ₹190 Cr 21.0% | ₹157 Cr 52.4% | ₹103 Cr |
| Investing CF | ₹-256 Cr 204.8% | ₹-84 Cr 68.5% | ₹-267 Cr 434.0% | ₹-50 Cr |
| Financing CF | ₹25 Cr 123.4% | ₹-107 Cr 208.1% | ₹99 Cr 320.0% | ₹-45 Cr |
| Net Cash Flow | ₹-1 Cr | ₹0 Cr 100.0% | ₹-11 Cr 237.5% | ₹8 Cr |
| Free Cash Flow | ₹56 Cr 43.4% | ₹99 Cr 176.7% | ₹-129 Cr 1533.3% | ₹9 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Debtor Days | 38d 5.6% | 36d 0.0% | 36d 0.0% | 36d |
| Inventory Days | 175d 12.5% | 200d 26.6% | 158d 13.2% | 182d |
| Days Payable | 206d 6.8% | 221d 20.1% | 184d 12.9% | 163d |
| Cash Conv. Cycle | 7d 50.0% | 14d 40.0% | 10d 81.8% | 55d |
| Working Capital Days | -15d 266.7% | 9d 550.0% | -2d 106.7% | 30d |
| ROCE | 33.0% 3.1% | 32.0% 28.0% | 25.0% | — |
Source: Screener.in · Lower days = better efficiency
About CORONA Remedies Limited
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.[1]
HealthcarePharmaceuticals & Biotechnology